Vitrolife AB (OSTO:VITR) Short-term investments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:VITR Vitrolife AB OSTO:VITR
76 GF Score
Price kr92.10
GF Value kr149.25
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Vitrolife AB Short-term investments?

Short-term investments only applies to insurance companies.

OSTO:VITR
76GF Score
Vitrolife AB OSTO:VITR
Short-term investments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Vitrolife AB (OSTO:VITR) Overvalued in 2026?

Based on GuruFocus' analysis, Vitrolife AB stock appears to be undervalued. The current stock price of kr92.10 is trading 38.3% below its estimated GF Value™ of kr149.25. GuruFocus considers Vitrolife AB to be Possible Value Trap.

Key valuation signals for OSTO:VITR:

  • Short-term investments:
  • GF Value™: kr149.25 vs. price of kr92.10 (38.3% below fair value)
  • GF Score™: 76/100 with 6 warning signs

No single metric tells the full story. See the OSTO:VITR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vitrolife AB Business Description

Address Box 9080, Gothenburg, SWE, 400 92
Vitrolife AB is a Swedish medical device and genetic testing company focused on the reproductive health and in vitro fertilization (IVF) market. It develops, manufactures, and sells products used throughout the IVF treatment chain, including culture media and solutions for embryo and gamete handling, cryopreservation and vitrification products, needles and catheters for egg retrieval and embryo transfer, and time-lapse incubation systems for embryo monitoring. Through its genetic testing operations, it offers preimplantation genetic testing and related laboratory services to IVF clinics. Its customers are fertility clinics, hospital laboratories, and research institutions worldwide. The company reports revenue across three geographic regions: EMEA, the Americas, and Asia-Pacific, with EMEA historically contributing the largest share. Revenue comes primarily from consumable product sales, supplemented by equipment and genetic testing services. Vitrolife also operates through acquired brands and subsidiaries serving IVF laboratories globally.
76GF Score

Get the complete analysis for OSTO:VITR

Short-term investments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr92.10
Price
kr149.25
GF Value